The inventors have discovered that substituting amino acid residues at positions 5 and/or 7 and/or 8 of the GnRH I (gonadotropin-releasing hormone) peptide sequence, and particularly removal of the arginine residue at position 8, results in elevated antiproliferative activitey. Furthermore, the introduction of certain D-amino acid residues at position 6 of the GnRH II peptide sequence results in elevated antiproliferative activity. This surprising discovery provides potent and selective agents for use in treating antiproliferative disorders, such as cancer.La présente invention concerne des agents, des compositions et des procédés utilisables en médecine. Linvention concerne en particulier des agents liés aux peptides GnRH.
